Cardiac Response Dynamics in Newly Diagnosed Light-Chain Amyloidosis Patients With Early and High-Quality Hematologic Response

Background: The goal of hematological response has been well established in the treatment of systemic light chain amyloidosis. However, the pattern of cardiac response remains unknown. Objectives: This study was designed to investigate the cardiac response dynamics in patients with an early and high...

Full description

Saved in:
Bibliographic Details
Main Authors: Cheng-yang Xu, MD, Ai Guan, MD, Lu Zhang, MD, Zhuang Tian, MD, Dao-bin Zhou, MD, Kai-ni Shen, MD, Jian Li, MD
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:JACC: Asia
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2772374724004071
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841553788101459968
author Cheng-yang Xu, MD
Ai Guan, MD
Lu Zhang, MD
Zhuang Tian, MD
Dao-bin Zhou, MD
Kai-ni Shen, MD
Jian Li, MD
author_facet Cheng-yang Xu, MD
Ai Guan, MD
Lu Zhang, MD
Zhuang Tian, MD
Dao-bin Zhou, MD
Kai-ni Shen, MD
Jian Li, MD
author_sort Cheng-yang Xu, MD
collection DOAJ
description Background: The goal of hematological response has been well established in the treatment of systemic light chain amyloidosis. However, the pattern of cardiac response remains unknown. Objectives: This study was designed to investigate the cardiac response dynamics in patients with an early and high-quality hematological response. Methods: This retrospective study included newly diagnosed patients who achieved a hematological response of very good partial response or better within 3 months after treatment beginning. Four cardiac response criteria were tested at fixed time points (3, 6, 12, and 24 months after therapy initiation): cardiac complete response, cardiac very good partial response, cardiac partial response (carPR), and cardiac no response. Results: A total of 201 patients were included, with the median follow-up 37.0 months (Q1-Q3: 18.0-56.5 months). The cardiac response reached a plateau at 24 months, while cardiac complete response, cardiac very good partial response, and carPR were achieved in 21.4% (28 of 131), 38.9% (51 of 131), and 20.6% (27 of 131) of the patients, respectively. At every fixed time point within 12 months after treatment initiation, patients who achieved a carPR or better consistently had better survival than did those who did not. At 3 months, an NT-proBNP concentration ≥3,716 pg/mL was the only factor associated with a decreased likelihood of achieving a carPR within 12 months (OR: 0.269; 95% CI: 0.137-0.512; P < 0.001). Conclusions: This study emphasizes the importance of monitoring cardiac response dynamics for disease surveillance. In patients who achieve early and high-quality hematological response, it is important to achieve carPR within 12 months.
format Article
id doaj-art-fb3f080afcae48c6a412df9aadbb9119
institution Kabale University
issn 2772-3747
language English
publishDate 2025-01-01
publisher Elsevier
record_format Article
series JACC: Asia
spelling doaj-art-fb3f080afcae48c6a412df9aadbb91192025-01-09T06:14:55ZengElsevierJACC: Asia2772-37472025-01-01517484Cardiac Response Dynamics in Newly Diagnosed Light-Chain Amyloidosis Patients With Early and High-Quality Hematologic ResponseCheng-yang Xu, MD0Ai Guan, MD1Lu Zhang, MD2Zhuang Tian, MD3Dao-bin Zhou, MD4Kai-ni Shen, MD5Jian Li, MD6Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Address for correspondence: Dr Kai-ni Shen, Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing 100730, People's Republic of China.Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; State Key Laboratory of Common Mechanism Research for Major Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Dr Jian Li, Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing 100730, People's Republic of China.Background: The goal of hematological response has been well established in the treatment of systemic light chain amyloidosis. However, the pattern of cardiac response remains unknown. Objectives: This study was designed to investigate the cardiac response dynamics in patients with an early and high-quality hematological response. Methods: This retrospective study included newly diagnosed patients who achieved a hematological response of very good partial response or better within 3 months after treatment beginning. Four cardiac response criteria were tested at fixed time points (3, 6, 12, and 24 months after therapy initiation): cardiac complete response, cardiac very good partial response, cardiac partial response (carPR), and cardiac no response. Results: A total of 201 patients were included, with the median follow-up 37.0 months (Q1-Q3: 18.0-56.5 months). The cardiac response reached a plateau at 24 months, while cardiac complete response, cardiac very good partial response, and carPR were achieved in 21.4% (28 of 131), 38.9% (51 of 131), and 20.6% (27 of 131) of the patients, respectively. At every fixed time point within 12 months after treatment initiation, patients who achieved a carPR or better consistently had better survival than did those who did not. At 3 months, an NT-proBNP concentration ≥3,716 pg/mL was the only factor associated with a decreased likelihood of achieving a carPR within 12 months (OR: 0.269; 95% CI: 0.137-0.512; P < 0.001). Conclusions: This study emphasizes the importance of monitoring cardiac response dynamics for disease surveillance. In patients who achieve early and high-quality hematological response, it is important to achieve carPR within 12 months.http://www.sciencedirect.com/science/article/pii/S2772374724004071cardiac response dynamicsimmunoglobulin light chain amyloidosisNT-proBNPretrospective study
spellingShingle Cheng-yang Xu, MD
Ai Guan, MD
Lu Zhang, MD
Zhuang Tian, MD
Dao-bin Zhou, MD
Kai-ni Shen, MD
Jian Li, MD
Cardiac Response Dynamics in Newly Diagnosed Light-Chain Amyloidosis Patients With Early and High-Quality Hematologic Response
JACC: Asia
cardiac response dynamics
immunoglobulin light chain amyloidosis
NT-proBNP
retrospective study
title Cardiac Response Dynamics in Newly Diagnosed Light-Chain Amyloidosis Patients With Early and High-Quality Hematologic Response
title_full Cardiac Response Dynamics in Newly Diagnosed Light-Chain Amyloidosis Patients With Early and High-Quality Hematologic Response
title_fullStr Cardiac Response Dynamics in Newly Diagnosed Light-Chain Amyloidosis Patients With Early and High-Quality Hematologic Response
title_full_unstemmed Cardiac Response Dynamics in Newly Diagnosed Light-Chain Amyloidosis Patients With Early and High-Quality Hematologic Response
title_short Cardiac Response Dynamics in Newly Diagnosed Light-Chain Amyloidosis Patients With Early and High-Quality Hematologic Response
title_sort cardiac response dynamics in newly diagnosed light chain amyloidosis patients with early and high quality hematologic response
topic cardiac response dynamics
immunoglobulin light chain amyloidosis
NT-proBNP
retrospective study
url http://www.sciencedirect.com/science/article/pii/S2772374724004071
work_keys_str_mv AT chengyangxumd cardiacresponsedynamicsinnewlydiagnosedlightchainamyloidosispatientswithearlyandhighqualityhematologicresponse
AT aiguanmd cardiacresponsedynamicsinnewlydiagnosedlightchainamyloidosispatientswithearlyandhighqualityhematologicresponse
AT luzhangmd cardiacresponsedynamicsinnewlydiagnosedlightchainamyloidosispatientswithearlyandhighqualityhematologicresponse
AT zhuangtianmd cardiacresponsedynamicsinnewlydiagnosedlightchainamyloidosispatientswithearlyandhighqualityhematologicresponse
AT daobinzhoumd cardiacresponsedynamicsinnewlydiagnosedlightchainamyloidosispatientswithearlyandhighqualityhematologicresponse
AT kainishenmd cardiacresponsedynamicsinnewlydiagnosedlightchainamyloidosispatientswithearlyandhighqualityhematologicresponse
AT jianlimd cardiacresponsedynamicsinnewlydiagnosedlightchainamyloidosispatientswithearlyandhighqualityhematologicresponse